Vimarsana
Biggest News Aggregation in the World

Devin Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Devin Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Devin Mclaughlin Today - Breaking & Trending Today

Couple facing drug trafficking charges - Vimarsana News

Couple facing drug trafficking charges

BURLINGTON — A Leicester woman and her longtime boyfriend, who was critically wounded when his brother was fatally shot last summer, pleaded not guilty this week to federal drug trafficking

Couple facing drug trafficking charges - Vimarsana News

Couple facing drug trafficking charges

BURLINGTON — A Leicester woman and her longtime boyfriend, who was critically wounded when his brother was fatally shot last summer, pleaded not guilty this week to federal drug trafficking

Novel AhR inhibitor shows tolerability, activity in advanced solid tumors - Vimarsana News

Novel AhR inhibitor shows tolerability, activity in advanced solid tumors

CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.In addition, the initial evaluation of biomarkers confirmed the biologic activity of BAY 2416964 (Bayer).

Source: healio.com
Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer - Vimarsana News

Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.The findings, presented at ASCO Annual Meeting, also showed tolerability of the combination with no new safety signals.

Source: healio.com
Trastuzumab deruxtecan shows 'broad activity' in HER2-expressing solid tumors - Vimarsana News

Trastuzumab deruxtecan shows 'broad activity' in HER2-expressing solid tumors

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable

Source: healio.com